drugset / Trial / NCT05077709
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Phase 2
Completed
63 enrolled
IO Biotech
Almac · collabMerck Sharp & Dohme LLC · collabNeoGenomics · collabTheradex · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Timeline
- Start
- 2022-04-11
- Primary completion
- 2025-11-30
- Completion
- 2026-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMSAPEPIMUT | Peptide | 85 ug | Subcutaneous |
| Subject | IO103 | Vaccine | 185 ug | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |